Alembic Pharmaceuticals, on Friday, said it, along with Breckenridge Pharmaceutical of the U.S., has settled a patent case with Novartis for Rivastigmine Tartrate capsules used for treating dementia.
The companies have settled their Paragraph IV patent litigation with Novartis for Rivastigmine Tartrate capsules, which are a generic version of Exelon capsules of Novartis, Alembic Pharmaceuticals said in a filing to the BSE.
Under the terms of the settlement agreement, Novartis had granted the two companies a licence to market their generic capsules before the date of the patent expiry, it added. The companies would launch the product immediately in the American market, Alembic Pharmaceuticals said.
Rivastigmine Tartrate capsules were prescribed for mild-to-moderate dementia of Alzheimer's type, and mild-to-moderate dementia associated with Parkinson's disease, the company said. The product would be available in the strengths of 1.5 mg, 3 mg, 4.5 mg and 6 mg, it added.